{"schema_version":"secwatch.filing_event.v1","accession":"0000200406-23-000073","form_type":"8-K","ticker":"JNJ","cik":"0000200406","company_name":"JOHNSON & JOHNSON","filed_at":"2023-07-20T23:59:59+00:00","discovered_at":"2026-05-14T18:03:36.178109+00:00","generated_at":"2026-06-13T05:51:04.656145+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"JNJ Q2 sales up 6.3% to $25.5B; raises FY guidance; Kenvue spin-off via exchange offer","bullets":["Q2 2023 sales $25.53B (+6.3%); operational sales growth 7.5% excluding COVID-19 vaccine 8.9%.","GAAP diluted EPS $1.96 (+8.9%); adjusted diluted EPS $2.80 (+8.1%).","FY 2023 adjusted operational sales ex-COVID vaccine and adjusted operational EPS guidance midpoints raised.","Board authorizes Kenvue share split-off via exchange offer as next step in separation."],"urls":{"canonical":"https://secwatch.observer/filing/0000200406-23-000073","json":"https://secwatch.observer/filing/0000200406-23-000073.json","markdown":"https://secwatch.observer/filing/0000200406-23-000073.md","text":"https://secwatch.observer/filing/0000200406-23-000073.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/0000200406-23-000073-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/jnj-20230720.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-13T05:51:04.656145+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"c839592a26e02d21100221d00ae9852194d46cd7","claim":"JOHNSON & JOHNSON reported second quarter ended July 2, 2023 results: revenue $25.5 Billion, net income $5,144, EPS $1.96. Guidance raised.","evidence_excerpt":"the second quarter ended July 2, 2023. --- EX-99.1 (EX-99.1) --- JOHNSON & JOHNSON REPORTS 2023 SECOND-QUARTER RESULTS: • 2023 Second-Quarter reported sales growth of 6.3% to $25.5 Billion with operational growth of 7.5%* and adjusted operational growth of 6.2%*. Operational growth excluding COVID-19 Vaccine of 8.9%* • Earnings per share (EPS) of $1.96 increasing","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/200406/000020040623000073/0000200406-23-000073-index.htm","confidence":0.89,"family_label":"Earnings Releases","details":[{"label":"Period","value":"second quarter ended July 2, 2023"},{"label":"Revenue","value":"$25.5 Billion"},{"label":"Net income","value":"$5,144"},{"label":"EPS","value":"$1.96"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}